Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 21, 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:05 ET
|
Cyclacel
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9...
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
August 03, 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 16:05 ET
|
Cyclacel
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of...
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
May 04, 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
April 12, 2022 07:00 ET
|
Cyclacel
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022 16:05 ET
|
Cyclacel
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 – -Cash Runway to Mid 2023- -Conference Call Scheduled for March 28, 2022, at...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
March 22, 2022 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 09, 2022 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
January 06, 2022 07:00 ET
|
Cyclacel
– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch...